Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Clustering of immune-mediated diseases in sarcoidosis.

Terwiel M, Grutters JC, van Moorsel CHM.

Curr Opin Pulm Med. 2019 Sep;25(5):539-553. doi: 10.1097/MCP.0000000000000598.

PMID:
31365389
2.

Correspondence for "Clinical epidemiology of familial sarcoidosis: A systematic literature review".

Terwiel M, van Moorsel CHM.

Respir Med. 2019 Jul 10. pii: S0954-6111(19)30236-7. doi: 10.1016/j.rmed.2019.07.012. [Epub ahead of print] No abstract available.

PMID:
31331737
3.

Clustering of immune-mediated diseases in sarcoidosis.

Terwiel M, Grutters JC, van Moorsel CHM.

Curr Opin Pulm Med. 2019 Jun 18. doi: 10.1097/MCP.0000000000000598. [Epub ahead of print]

PMID:
31219835
4.

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis.

Jacob J, Bartholmai BJ, van Moorsel CHM, Rajagopalan S, Devaraj A, van Es HW, Moua T, van Beek FT, Clay R, Veltkamp M, Kokosi M, de Lauretis A, Judge EP, Burd T, Peikert T, Karwoski R, Maldonado F, Renzoni E, Maher TM, Altmann A, Wells AU.

Eur Respir J. 2019 Jun 13. pii: 1802341. doi: 10.1183/13993003.02341-2018. [Epub ahead of print] No abstract available.

PMID:
31196945
5.

Precision medicine: integration of genetics and functional genomics in prediction of bronchiolitis obliterans after lung transplantation.

Luijk B, Vos R, van Moorsel CHM.

Curr Opin Pulm Med. 2019 May;25(3):308-316. doi: 10.1097/MCP.0000000000000579.

PMID:
30883449
6.

Long-term expanding human airway organoids for disease modeling.

Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H.

EMBO J. 2019 Feb 15;38(4). pii: e100300. doi: 10.15252/embj.2018100300. Epub 2019 Jan 14.

7.

Clinical epidemiology of familial sarcoidosis: A systematic literature review.

Terwiel M, van Moorsel CHM.

Respir Med. 2019 Mar;149:36-41. doi: 10.1016/j.rmed.2018.11.022. Epub 2018 Dec 13. Review.

PMID:
30587386
8.

Bronchoalveolar lavage characteristics correlate with HLA tag SNPs in patients with Löfgren's syndrome and other sarcoidosis.

Karakaya B, Schimmelpennink MC, Kocourkova L, van der Vis JJ, Meek B, Grutters JC, Petrek M, van Moorsel CHM.

Clin Exp Immunol. 2019 May;196(2):249-258. doi: 10.1111/cei.13257. Epub 2019 Jan 24.

PMID:
30585624
9.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

10.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

11.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.

N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20.

12.

Systematic review of drug effects in humans and models with surfactant-processing disease.

Klay D, Hoffman TW, Harmsze AM, Grutters JC, van Moorsel CHM.

Eur Respir Rev. 2018 Jul 11;27(149). pii: 170135. doi: 10.1183/16000617.0135-2017. Print 2018 Sep 30.

13.

The aging lung: tissue telomere shortening in health and disease.

Everaerts S, Lammertyn EJ, Martens DS, De Sadeleer LJ, Maes K, van Batenburg AA, Goldschmeding R, van Moorsel CHM, Dupont LJ, Wuyts WA, Vos R, Gayan-Ramirez G, Kaminski N, Hogg JC, Janssens W, Verleden GM, Nawrot TS, Verleden SE, McDonough JE, Vanaudenaerde BM.

Respir Res. 2018 May 11;19(1):95. doi: 10.1186/s12931-018-0794-z.

14.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

15.

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis.

de Brouwer B, Drent M, van den Ouweland JMW, Wijnen PA, van Moorsel CHM, Bekers O, Grutters JC, White ES, Janssen R.

Respir Res. 2018 Mar 20;19(1):45. doi: 10.1186/s12931-018-0747-6.

16.

Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis.

Snetselaar R, van Oosterhout MFM, Grutters JC, van Moorsel CHM.

Front Med (Lausanne). 2018 Feb 27;5:41. doi: 10.3389/fmed.2018.00041. eCollection 2018.

17.

Cell Type-Specific Quantification of Telomere Length and DNA Double-strand Breaks in Individual Lung Cells by Fluorescence In Situ Hybridization and Fluorescent Immunohistochemistry.

van Batenburg AA, Kazemier KM, Peeters T, van Oosterhout MFM, van der Vis JJ, Grutters JC, Goldschmeding R, van Moorsel CHM.

J Histochem Cytochem. 2018 Jul;66(7):485-495. doi: 10.1369/0022155418761351. Epub 2018 Mar 12.

18.
19.

Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF).

Wiertz IA, van Moorsel CHM, Vorselaars ADM, Quanjel MJR, Grutters JC.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702519. doi: 10.1183/13993003.02519-2017. Print 2018 Apr. No abstract available.

PMID:
29496758
20.

Pulmonary phenotypes associated with genetic variation in telomere-related genes.

Hoffman TW, van Moorsel CHM, Borie R, Crestani B.

Curr Opin Pulm Med. 2018 May;24(3):269-280. doi: 10.1097/MCP.0000000000000475. Review.

PMID:
29474209
21.

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis.

Spoorenberg SMC, Vestjens SMT, Voorn GP, van Moorsel CHM, Meek B, Zanen P, Rijkers GT, Bos WJW, Grutters JC; Ovidius study group.

PLoS One. 2018 Jan 11;13(1):e0190575. doi: 10.1371/journal.pone.0190575. eCollection 2018.

22.

Short telomere length in IPF lung associates with fibrotic lesions and predicts survival.

Snetselaar R, van Batenburg AA, van Oosterhout MFM, Kazemier KM, Roothaan SM, Peeters T, van der Vis JJ, Goldschmeding R, Grutters JC, van Moorsel CHM.

PLoS One. 2017 Dec 27;12(12):e0189467. doi: 10.1371/journal.pone.0189467. eCollection 2017.

23.

To progress understanding of disease triggers and modifiers in sarcoidosis, stratification is the key.

van Moorsel CHM.

Eur Respir J. 2017 Dec 14;50(6). pii: 1702002. doi: 10.1183/13993003.02002-2017. Print 2017 Dec. No abstract available.

24.

Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.

Wiertz IA, Wuyts WA, van Moorsel CHM, Vorselaars ADM, van Es HW, van Oosterhout MFM, Grutters JC.

Respirology. 2018 Mar;23(3):311-317. doi: 10.1111/resp.13230. Epub 2017 Dec 5.

25.

Löfgren's Syndrome: Diagnosis, Management, and Disease Pathogenesis.

Karakaya B, Kaiser Y, van Moorsel CHM, Grunewald J.

Semin Respir Crit Care Med. 2017 Aug;38(4):463-476. doi: 10.1055/s-0037-1602380. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750461
26.

SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility-A Joint Analysis in Four European Populations.

Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CHM, Eklund A, Grutters JC, Kolek V, Mrazek F, Kishore A, Padyukov L, Pietinalho A, Ronninger M, Seppänen M, Selroos O, Lokki ML.

Front Immunol. 2017 Apr 19;8:422. doi: 10.3389/fimmu.2017.00422. eCollection 2017.

27.

YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia.

Spoorenberg SM, Vestjens SM, Rijkers GT, Meek B, van Moorsel CH, Grutters JC, Bos WJ; Ovidius Study Group.

Respirology. 2017 Apr;22(3):542-550. doi: 10.1111/resp.12924. Epub 2016 Oct 26.

28.

Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Orphanet J Rare Dis. 2016 Aug 31;11(1):115. doi: 10.1186/s13023-016-0497-9.

29.

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Chest. 2016 Jul;150(1):251-3. doi: 10.1016/j.chest.2016.04.030. No abstract available.

30.

Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?

Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Meek B, Claessen AM, Rijkers GT, Grutters JC.

Eur Respir J. 2016 Oct;48(4):1242-1245. doi: 10.1183/13993003.00709-2016. Epub 2016 Jul 7. No abstract available.

31.

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.

Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, Deneer VH, Grutters JC.

Respir Med. 2016 Jun;115:72-7. doi: 10.1016/j.rmed.2016.04.011. Epub 2016 Apr 23.

32.

Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.

Verwoerd A, Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Grutters JC, Claessen AM.

Clin Exp Immunol. 2016 Aug;185(2):263-70. doi: 10.1111/cei.12808. Epub 2016 Jul 12.

33.

TINF2 Gene Mutation in a Patient with Pulmonary Fibrosis.

Hoffman TW, van der Vis JJ, van Oosterhout MF, van Es HW, van Kessel DA, Grutters JC, van Moorsel CH.

Case Rep Pulmonol. 2016;2016:1310862. doi: 10.1155/2016/1310862. Epub 2016 Mar 20.

34.

Managing FDG PET-positive sarcoidosis: "a riddle wrapped in a mystery inside an enigma".

Vorselaars AD, Crommelin HA, van Moorsel CH, Grutters JC.

Eur Respir J. 2016 Jan;47(1):347-8. doi: 10.1183/13993003.01438-2015. No abstract available.

35.

Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias.

van der Vis JJ, Snetselaar R, Kazemier KM, ten Klooster L, Grutters JC, van Moorsel CH.

Respirology. 2016 May;21(4):712-7. doi: 10.1111/resp.12728. Epub 2015 Dec 24.

36.

High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences.

Rivera NV, Ronninger M, Shchetynsky K, Franke A, Nöthen MM, Müller-Quernheim J, Schreiber S, Adrianto I, Karakaya B, van Moorsel CH, Navratilova Z, Kolek V, Rybicki BA, Iannuzzi MC, Petrek M, Grutters JC, Montgomery C, Fischer A, Eklund A, Padyukov L, Grunewald J.

Am J Respir Crit Care Med. 2016 May 1;193(9):1008-22. doi: 10.1164/rccm.201507-1372OC.

37.

SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia.

van Moorsel CH, Ten Klooster L, van Oosterhout MF, de Jong PA, Adams H, Wouter van Es H, Ruven HJ, van der Vis JJ, Grutters JC.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1249-52. doi: 10.1164/rccm.201504-0675LE. No abstract available.

PMID:
26568241
38.

Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs.

van Moorsel CH, Hoffman TW, van Batenburg AA, Klay D, van der Vis JJ, Grutters JC.

Biomed Res Int. 2015;2015:304186. doi: 10.1155/2015/304186. Epub 2015 Oct 11. Review.

39.

Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation.

ten Klooster L, Nossent GD, Kwakkel-van Erp JM, van Kessel DA, Oudijk EJ, van de Graaf EA, Luijk B, Hoek RA, van den Blink B, van Hal PT, Verschuuren EA, van der Bij W, van Moorsel CH, Grutters JC.

Lung. 2015 Dec;193(6):919-26. doi: 10.1007/s00408-015-9794-7. Epub 2015 Sep 24.

PMID:
26404700
40.

Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis?

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2015;7(6):601. doi: 10.2217/imt.15.25. Epub 2015 Jun 22. No abstract available.

41.

Telomere length in interstitial lung diseases.

Snetselaar R, van Moorsel CHM, Kazemier KM, van der Vis JJ, Zanen P, van Oosterhout MFM, Grutters JC.

Chest. 2015 Oct;148(4):1011-1018. doi: 10.1378/chest.14-3078.

PMID:
25973743
42.

Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.

Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, van Moorsel CH, Grutters JC.

Eur Respir J. 2015 Jul;46(1):175-85. doi: 10.1183/09031936.00227014. Epub 2015 Apr 30.

43.

Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis.

Ten Klooster L, van Moorsel CH, Kwakkel-van Erp JM, van Velzen-Blad H, Grutters JC.

Clin Exp Immunol. 2015 Aug;181(2):357-61. doi: 10.1111/cei.12636. Epub 2015 Jun 8.

44.

Non-specific and Usual Interstitial Pneumonia, Short-Term Survival After Surgical Biopsy.

Knipscheer BJ, van Moorsel CH, Grutters JC.

Lung. 2015 Jun;193(3):449-50. doi: 10.1007/s00408-015-9721-y. Epub 2015 Apr 2. No abstract available.

45.

Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency.

Verwoerd A, Vorselaars AD, van Moorsel CH, Bos WJ, van Velzen-Blad H, Grutters JC.

Eur Respir J. 2015 Jul;46(1):277-80. doi: 10.1183/09031936.00005315. Epub 2015 Mar 5. No abstract available.

46.

ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.

Vorselaars AD, van Moorsel CH, Zanen P, Ruven HJ, Claessen AM, van Velzen-Blad H, Grutters JC.

Respir Med. 2015 Feb;109(2):279-85. doi: 10.1016/j.rmed.2014.11.009. Epub 2014 Nov 29.

47.

Anti-TNF therapeutics for the treatment of sarcoidosis.

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2014;6(10):1127-43. doi: 10.2217/imt.14.65. Review.

PMID:
25428650
48.

Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias.

Korthagen NM, van Moorsel CH, Zanen P, Ruven HJ, Grutters JC.

Lung. 2014 Dec;192(6):975-80. doi: 10.1007/s00408-014-9647-9. Epub 2014 Oct 2.

PMID:
25274153
49.

Predator-prey interactions between shell-boring beetle larvae and rock-dwelling land snails.

Baalbergen E, Helwerda R, Schelfhorst R, Castillo Cajas RF, van Moorsel CH, Kundrata R, Welter-Schultes FW, Giokas S, Schilthuizen M.

PLoS One. 2014 Jun 25;9(6):e100366. doi: 10.1371/journal.pone.0100366. eCollection 2014.

50.

Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in Löfgren's syndrome.

Karakaya B, van Moorsel CH, van der Helm-van Mil AH, Huizinga TW, Ruven HJ, van der Vis JJ, Grutters JC.

Cytokine. 2014 Oct;69(2):272-6. doi: 10.1016/j.cyto.2014.05.020. Epub 2014 Jun 17.

PMID:
24951298

Supplemental Content

Loading ...
Support Center